No impairment of antipyrine elimination by the selective anticholinergic drug pirenzepine.
The elimination kinetics of antipyrine have been established under basal environmental conditions in 6 healthy volunteers. Concentrations of antipyrine in serum were measured by a relatively fast high-pressure liquid chromatography method using a radial-compression chromatographic system. Pretreatment of the subjects with therapeutic doses of pirenzepine over 5 days had no significant effect on the absorption, distribution, and elimination of antipyrine. These results suggest that pirenzepine is free of the inhibition of the hepatic mixed function oxidase system produced by cimetidine.
D000328:Adult; D000897:Anti-Ulcer Agents / Q000494:pharmacology; D000983:Antipyrine / Q000378:metabolism*; D001570:Benzodiazepinones / Q000494:pharmacology*; D002927:Cimetidine / Q000494:pharmacology; D004347:Drug Interactions; D006207:Half-Life; D006801:Humans; D008099:Liver / Q000201:enzymology; D008297:Male; D006899:Mixed Function Oxygenases / Q000037:antagonists & inhibitors / Q000378:metabolism; D010276:Parasympatholytics / Q000494:pharmacology*; D010890:Pirenzepine
D000897:Anti-Ulcer Agents; D001570:Benzodiazepinones; D010276:Parasympatholytics; D010890:Pirenzepine; D002927:Cimetidine; D006899:Mixed Function Oxygenases; D000983:Antipyrine